Using troxerutin to prevent blood clots in COVID-19 patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy of troxerutin in preventing thrombotic events in patients diagnosed with COVID-19, both mild and severe. Participants will be randomly assigned to receive either troxerutin or a placebo daily for seven days, with follow-up visits on specific days for health assessments. The study will monitor the occurrence of thrombotic events, bleeding events, and any adverse effects associated with troxerutin. The goal is to determine if troxerutin can effectively reduce the risk of blood clots in these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

As long as the patient meets all of the following conditions, adult patients aged 18 and above are eligible for admission:

► COVID-19 patients, defined as: positive RT-PCR (upper respiratory tract or lower respiratory tract) for SARS-CoV-2.

Mild COVID-19 patients are defined as:

Symptomatic patients meeting the case definition for COVID-19 without evidence of hypoxia or pneumonia. Common symptoms include fever, cough, fatigue, anorexia, dyspnea, and myalgia. Other nonspecific symptoms include sore throat, nasal congestion, headache, diarrhea, nausea/vomiting, and loss of smell/taste.

Severe COVID-19 patients are defined as:

Adolescents or adults with clinical signs of pneumonia (i.e., fever, cough, dyspnea, tachypnea) plus one of the following:

1. Respiratory rate ≥30 breaths/min
2. Severe respiratory distress
3. Oxygen saturation (SpO₂) ≤90% in room air
4. Progressive deterioration of clinical symptoms with lung imaging showing significant progression of lesions (\>50%) within 24 to 48 hours.

   * Written informed consent provided according to Chinese law (by the patient, legal guardian, or deferred consent in emergencies).

Exclusion Criteria:

Patients with any of the following conditions will be excluded from the study:

* Pregnant or lactating women.
* Postpartum (within 6 weeks).
* Extreme weight (100 kilograms).
* Clinical need for heparin therapy.
* Bleeding related to coagulation disorders, acute clinically significant bleeding, active gastrointestinal ulcers, or any organic lesions with high bleeding risk.
* Platelet count \<50 x 10\^9/L.
* Surgery within the last 15 days, or within 24 hours after spinal or epidural anesthesia.
* History of intracranial hemorrhage, large ischemic stroke, known intracranial malformation or tumor, acute infective endocarditis.
* Severe renal impairment (creatinine clearance \<30 mL/min).
* Iodine allergy.
* Long-term use of oxygen supplementation.
* Moribund patients or those expected to die during the current hospitalization due to underlying disease.
* Patients deprived of freedom and those undergoing institutional psychiatric care.
* Ward of the state or under guardianship.
* Participation in other anticoagulant intervention studies.

Where it's running

• Shaoxing central hospital
  Shaoxing, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Xu Li, PhD
• Email: lixu@westlake.edu.cn
• Phone: 13811635032

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Westlake Aging Cohort: following 55+ to map aging and cognitive changes

  A large observational study in Hangzhou will follow 2,800 adults aged 55–90 to see how aging, cognition, and neurodegenerative diseases relate to biology over time.

  Recruiting at 2 sites Westlake University · Hangzhou, Zhejiang and 1 other locations · NCT07373444

• Exploring Clostridioides Difficile Infections in Infants

  This study looks at Clostridioides difficile infections in babies under 2 years old to see how it affects them and what might put them at risk.

  Recruiting Westlake University · Hangzhou, Zhejiang · NCT06788769

• A study on healthy aging among older adults in Lishui, China

  This study looks at how diet and lifestyle affect healthy aging in older adults in Lishui, China, to see if it can help create personalized tips for living longer.

  Recruiting Westlake University · Lishui, Zhejiang · NCT05256251

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.